Vertex Pharmaceuticals Incorporated
NMS: VRTXLive Quote
📈 ZcoreAI Score
Our AI model analyzes Vertex Pharmaceuticals Incorporated's price action across multiple timeframes using regression channels and statistical scoring.
Get VRTX Z-Score →About Vertex Pharmaceuticals Incorporated
Healthcare
Biotechnology
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
📊 Fundamental Analysis
Vertex Pharmaceuticals Incorporated demonstrates exceptional profitability, with a profit margin of 32.9%.
The company recently reported 9.5% revenue growth, which is above average for the Healthcare sector.
Return on Equity (ROE) is 22.5%, which exceeds the Healthcare sector average, reflecting efficient capital allocation.
At a current price of $436.27, VRTX currently sits at the 50th percentile of its 52-week range (Range: $362.50 - $510.77).
💰 Valuation Insight
VRTX is valued broadly in line with the sector at a PE of 28.50. Analysts expect earnings growth, as indicated by a lower forward PE.
🏥 Financial Health
✅
Profit Margin
Excellent
✅
Debt/Equity
Excellent
⚠️
Revenue Growth
Moderate
⚠️
Return on Equity
Moderate
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$110.97B
Trailing P/E
28.50
Forward P/E
19.96
Beta (5Y)
0.37
52W High
$510.77
52W Low
$362.50
Avg Volume
1.47M
Day High
Day Low